Alumis Inc. (ALMS) vs Janux Therapeutics, Inc. (JANX)
Alumis Inc. and Janux Therapeutics, Inc. are both Biotechnology companies. Alumis Inc. and Janux Therapeutics, Inc. are of similar size ($1.0B and $985.9M). Janux Therapeutics, Inc. has the higher net margin (−427.5% vs −5,933.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Janux Therapeutics, Inc. leads on 11 and Alumis Inc. on 2.
Valuation
Profitability
| Metric | ALMS | JANX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (6,204.39%) | (598.15%) | 0.00% |
| Net margin | (5,933.45%) | (427.47%) | 0.00% |
| Free cash flow margin | (4,755.33%) | (174.69%) | 0.00% |
| Return on equity | (93.65%) | (10.70%) | (57.72%) |
| Return on assets | (74.94%) | (10.06%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack